樂歌股份(300729.SZ):上海分公司註銷完成
格隆匯12月27日丨樂歌股份(300729.SZ)公佈,公司於2019年10月25日召開了第四屆董事會第五次會議,審議通過了《關於註銷分公司的議案》,公司基於整體戰略規劃,為了優化組織架構,提高管理效率,從而提高公司整體經營效益,決定註銷樂歌人體工學科技股份有限公司上海分公司(“上海分公司”)。
近日,公司收到了上海市市場監督管理局發出的《准予註銷登記通知書》,准予上海分公司註銷登記。至此,上海分公司註銷登記手續已辦理完畢。
上海分公司註銷完成後,公司的合併報表範圍將相應發生變化,但不會對公司整體業務發展和盈利水平產生重大影響,不會對公司合併報表產生實質性的影響,不會損害公司及全體股東利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.